Source:http://linkedlifedata.com/resource/pubmed/id/16247421
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-12-16
|
pubmed:abstractText |
We analysed the outcome of 92 consecutive unrelated donor haematopoietic cell transplantations (UD-HCTs) performed in Spain to treat adult patients with CML in the first chronic phase (1CP). Patients' and donors' median age was 32 (15-49) and 36 (22-56) years, respectively. In all, 73 pairs (79%) matched for A, B+/-C and DRB1+/-DQB1 loci and 19 had > or =1 mismatch. Their probability of survival and disease-free survival at 4 years were 50 and 46%, respectively. Pretransplant factors associated with a better survival were patient age <25 years (P=0.035), donor age < or =36 years (P=0.012), use of cyclosporine since day -7 (P=0.001), and matching 8/8, 9/10 or 10/10 loci at allele level (P=0.003). In multivariate analysis only donor age (P=0.003; RR=3.1 (95% CI: 1.3-7.1)) and degree of HLA-matching (P=0.009; RR: 7.7 (95% CI: 1.8-33)) maintained their significance. The addition of these two variables to the EBMT prognostic score allowed an adequate risk assessment for patients receiving a UD-HCT during 1CP. Our analysis shows that in patients with a young and fully allele-matched donor, UD-HCT should be considered in the initial therapeutic algorithm due to its excellent outcome (92% survival at 2 years).
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0268-3369
|
pubmed:author |
pubmed-author:CañizoCC,
pubmed-author:CabreraRR,
pubmed-author:CarrerasEE,
pubmed-author:Fernández-RañadaJ MJM,
pubmed-author:Gómez-GarcíaVV,
pubmed-author:IriondoAA,
pubmed-author:JiménezMM,
pubmed-author:LópezJJ,
pubmed-author:MartínCC,
pubmed-author:MartínezCC,
pubmed-author:MartínezFF,
pubmed-author:RoviraMM,
pubmed-author:SanzGG,
pubmed-author:SierraJJ,
pubmed-author:TorresAA,
pubmed-author:VallejoCC,
pubmed-author:de la CámaraRR
|
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
33-40
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:16247421-Adolescent,
pubmed-meshheading:16247421-Adult,
pubmed-meshheading:16247421-Age Factors,
pubmed-meshheading:16247421-Disease-Free Survival,
pubmed-meshheading:16247421-Female,
pubmed-meshheading:16247421-HLA-DQ Antigens,
pubmed-meshheading:16247421-HLA-DR Antigens,
pubmed-meshheading:16247421-HLA-DRB1 Chains,
pubmed-meshheading:16247421-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:16247421-Histocompatibility Testing,
pubmed-meshheading:16247421-Humans,
pubmed-meshheading:16247421-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:16247421-Living Donors,
pubmed-meshheading:16247421-Male,
pubmed-meshheading:16247421-Middle Aged,
pubmed-meshheading:16247421-Prognosis,
pubmed-meshheading:16247421-Transplantation, Homologous
|
pubmed:year |
2006
|
pubmed:articleTitle |
Donor age and degree of HLA matching have a major impact on the outcome of unrelated donor haematopoietic cell transplantation for chronic myeloid leukaemia.
|
pubmed:affiliation |
Spanish Bone Marrow Donor Registry (REDMO), IDIBAPS, Barcelona, Spain. carreras@clinic.ub.es
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|